

Kiribati support for Pneumococcal vaccine

This decision letter sets out the Programme Terms of a Programme.

1. Country: Kiribati			
2. Grant number: 16-KIR-12c-X			
3. Date of decision letter: 19 November 2015			
4. Date of the Partnership Framework Agreement: 22 July 2014			
5. Programme title: New vaccine support (NVS), Pneumococcal Routine			
6. Vaccine type: Pneumococcal			
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV13), 1 dose per vial, LIQUID			
8. Programme duration¹: 2013 - 2016			
9. Programme budget (indicative): (subject to the terms of the Partnership Framework Agreement)			
	2013 - 2015	2016	Total ²
Programme budget (US\$)	US\$123,761 ³	US\$20,000	US\$143,761
10. Vaccine introduction grant (in US\$): Not applicable			
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ⁴			
Type of supplies to be purchased with Gavi funds in each year	2013 - 2015	2016	
Number of Pneumococcal vaccines doses		1,800	
Number of AD syringes		2,000	
Number of re-constitution syringes		-	
Number of safety boxes		25	
Annual Amounts (US\$)	US\$123,761 ⁵	US\$20,000	
12. Procurement agency: UNICEF Country shall release its co-financing payments each year to UNICEF.			
13. Self-procurement: Not applicable			

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years.

14. Co-financing obligations: Reference code: 16-KIR-12c-X-C

According to the co-financing policy, Country falls within the Accelerated transition group.

The following table summarises the co-financing payments and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2016
Number of vaccine doses	7,200
Number of AD syringes	6,000
Number of re-constitution syringes	-
Number of safety boxes	100
Value of vaccine doses (US\$)	US\$22,356
Total co-financing payments (US\$) (including freight)	US\$24,500

15. Operational support for campaigns: Not applicable

16. Additional reporting requirements: Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future annual amounts.

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2016
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat

17. Financial clarifications: Not applicable

18. Other conditions: Not applicable

Country is reminded of its obligations under the Partnership Framework Agreement in respect of insurance and is requested to inform the Gavi Secretariat on the steps it has taken in this regard.

Signed by,



On behalf of Gavi

Hind Khatib-Othman

Managing Director, Country Programmes

19 November 2015